

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai Kindly Medical Instruments Co., Ltd.\***

**上海康德萊醫療器械股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1501)**

## **SUPPLEMENTAL ANNOUNCEMENT CONNECTED TRANSACTION**

Reference is made to the announcement of Shanghai Kindly Medical Instruments Co., Ltd.\* 上海康德萊醫療器械股份有限公司 (the “**Company**”) dated August 18, 2022 in relation to the establishment of and investment in the Chengdu Huaige Fund (the “**Announcement**”). Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

This announcement is made to provide supplemental information on the identities of the ultimate beneficial owners of Xiezhao and Chengdu Biological.

### **INFORMATION OF XIEZHAO AND ITS ULTIMATE BENEFICIAL OWNERS**

As disclosed in the Announcement, Xiezhao is a limited liability company established in the PRC on September 7, 2017. It is principally engaged in enterprise management consulting and equity investment. Based on the information available to the Company, as at the date of this announcement, Xiezhao is owned as to 90.0% of by Mr. Zhang Min (張敏) and as to 10.0% by Ms. Nie Juan (聶娟). To the best of the Directors' knowledge, information and belief having made all reasonable enquiry, each of Mr. Zhang Min and Ms. Nie Juan is independent from the Company and the Company's connected persons.

## INFORMATION OF CHENGDU BIOLOGICAL AND ITS ULTIMATE BENEFICIAL OWNERS

As disclosed in the Announcement, Chengdu Biological is a limited partnership established in the PRC on September 11, 2019. It is principally engaged in equity investment. Based on the information available to the Company, as at the date of this announcement, Chengdu Biological is owned as to 1.0% by Chengdu Biological City Equity Investment Fund Management Co., Ltd.\* (成都生物城股權投資基金管理有限公司) (“**Chengdu Biological Management**”) as the general partner and as to 99.0% by Chengdu Tianfu International Biological City Development Group Co., Ltd.\* (成都天府國際生物城發展集團有限公司) (“**Chengdu Tianfu**”) as the limited partner. Chengdu Biological Management is wholly owned by Chengdu Biological City Equity Investment Co., Ltd.\* (成都生物城股權投資有限公司), which is in turn wholly owned by Chengdu Tianfu. Chengdu Tianfu is in turn owned as to 54.0% by Chengdu High-tech Industrial Development Zone Financial Bureau\* (成都高新技術產業開發區財政金融局), 36.0% by Chengdu Shuangliu District State-owned Assets Supervision and Administration and Financial Work Bureau\* (成都市雙流區國有資產監督管理和金融工作局) and 10.0% by Sichuan Provincial Financial Department\* (四川省財政廳), each of which is a PRC governmental body.

Save as supplemented and disclosed above, the contents in the Announcement remain unchanged. This supplemental announcement is supplemental to and should be read in conjunction with the Announcement.

By order of the Board  
**Shanghai Kindly Medical Instruments Co., Ltd.\***  
上海康德萊醫療器械股份有限公司  
**Dr. Liang Dongke**  
*Chairman*

Shanghai, the PRC  
August 23, 2022

*As at the date of this announcement, the Board comprises Dr. Liang Dongke and Mr. Lin Sen as executive Directors, Mr. Zhang Weixin, Ms. Chen Hongqin, Dr. Song Yuan and Mr. Wang Ruiqin as non-executive Directors, and Mr. Jian Xigao, Mr. Hui Hung Kwan and Mr. Xu Congli as independent non-executive Directors.*

\* For identification purposes only